Medimaps Group S.A. and Radiobotics ApS are merging to form a global AI-driven musculoskeletal imaging platform that combines bone microarchitecture analysis with trauma-detection tools.

The portfolio features RBfracture, TBS Reveal, and TBS Osteo, which detect trauma findings, assess bone fragility, and predict fracture risk within PACS-enabled workflows.

Executives from both sides, including Didier Hans and Peter Ulvskjold, committed to integrating technologies and expanding access to MSK AI solutions.

The group will operate in 90 countries, leveraging a shared distribution network while preserving the individual leadership and identities of both brands.

The combined entity will maintain Medimaps Group and Radiobotics as brands, supported by joint R&D and commercial collaboration.

Senior leadership from both companies will retain key roles, forming an executive team to guide the merged organization and preserve MSK expertise.

The combined company will automate fracture detection, enable opportunistic bone fragility assessment, and predict fracture risk across the care continuum, aiming to reach 90 markets including the United States for hospitals, clinics, and imaging centers.

Transaction terms are not disclosed, but the companies expect to broaden access in 90 markets, leveraging combined clinical expertise and distribution networks.

Closing is contingent on Danish foreign direct investment approval and other customary closing conditions, with no financial terms disclosed.

The deal requires Danish FDI approval and other standard conditions, with completion anticipated after regulatory clearance.

Both brands will retain their identities while sharing R&D and commercial collaboration under a unified executive leadership team.

Regulatory approval and customary closing conditions are needed, with completion expected once clearance is obtained.